Inactive Instrument

Paratek Pharmaceuticals, Inc.

PRTK

US6993743029

Paratek Pharmaceuticals, Inc Announces Executive Changes

January 04, 2017 at 07:36 am EST

On January 4, 2017, Paratek Pharmaceuticals, Inc. announced several leadership promotions, including the promotion of Evan Loh, age 57, to President, Chief Operating Officer and Chief Medical Officer of the company, effective January 1, 2017. Prior to the promotion, Dr. Loh served as the company's president and Chief Medical Officer since October 2014. Additionally, the company announced that Evan Tzanis has been promoted to Senior Vice President, Clinical Development and Clinical Operations. Evan has successfully led clinical development efforts at Paratek since joining Paratek in 2014. Jeanne Jew, who joined Paratek in 2015, has been promoted to Senior Vice President, Business Development. Both Mr. Tzanis and Ms. Jew will report to Evan Loh.

Latest news about Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	Mar. 05	CI
Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	Jan. 16	CI
Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer	Jan. 16	CI
Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals	23-09-22	MT
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals	23-09-21	RE
Paratek Pharmaceuticals, Inc. Announces Board Changes	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from NASDAQ Composite Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P TMI Index	23-09-21	CI
Gurnet Point Capital Limited and Novo Holdings A/S acquired acquire Paratek Pharmaceuticals, Inc. from a group of shareholders.	23-09-20	CI
Paratek Pharmaceuticals Says Shareholders Approved $462 Million Acquisition by Gurnet Point Capital, Novo Holdings	23-09-18	MT
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q2 Revenue $40M	23-08-03	MT
Paratek Pharmaceuticals' Investor NexPoint Sends Demand Letter for Records of Proposed Takeover by Gurnet	23-07-11	MT
Declaration of Voting Results by Paratek Pharmaceuticals	23-07-11	CI
Paratek Modifies Contract With US Government's BARDA to Advance Nuzyra Antibiotic	23-07-10	MT
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of NuzyraÂ®? (Omadacycline) for Post-Exposure Prophylaxis and Treatment of Pulmonary Anthrax	23-07-10	CI
Paratek Pharmaceuticals Says 'Disagrees' With NexPoint Asset Management's Accusations	23-06-27	MT
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Advisors Letter	23-06-27	CI
Paratek Pharmaceuticals' NUZYRA Therapy for Nontuberculous Mycobacterial Lung Disease Gets EU Positive Opinion	23-06-27	MT
NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals	23-06-27	CI
Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	23-06-12	CI
North American Morning Briefing : Nasdaq Futures -2-	23-06-08	DJ
HC Wainwright Downgrades Paratek Pharmaceuticals to Neutral From Buy, Price Target is $2.15	23-06-07	MT
Jefferies Downgrades Paratek Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.15 From $5	23-06-07	MT

Chart Paratek Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals